Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19
Suchitra Kamle, … , Chun Geun Lee, Jack A. Elias
Suchitra Kamle, … , Chun Geun Lee, Jack A. Elias
Published November 8, 2021
Citation Information: JCI Insight. 2021;6(21):e148749. https://doi.org/10.1172/jci.insight.148749.
View: Text | PDF
Research Article COVID-19 Therapeutics

Chitinase 3-like-1 is a therapeutic target that mediates the effects of aging in COVID-19

  • Text
  • PDF
Abstract

COVID-19 is caused by SARS-CoV-2 (SC2) and is more prevalent and severe in elderly and patients with comorbid diseases (CM). Because chitinase 3-like-1 (CHI3L1) is induced during aging and CM, the relationships between CHI3L1 and SC2 were investigated. Here, we demonstrate that CHI3L1 is a potent stimulator of the SC2 receptor angiotensin converting enzyme 2 (ACE2) and viral spike protein priming proteases (SPP), that ACE2 and SPP are induced during aging, and that anti-CHI3L1, kasugamycin, and inhibitors of phosphorylation abrogate these ACE2- and SPP-inductive events. Human studies also demonstrate that the levels of circulating CHI3L1 are increased in the elderly and patients with CM, where they correlate with COVID-19 severity. These studies demonstrate that CHI3L1 is a potent stimulator of ACE2 and SPP, that this induction is a major mechanism contributing to the effects of aging during SC2 infection, and that CHI3L1 co-opts the CHI3L1 axis to augment SC2 infection. CHI3L1 plays a critical role in the pathogenesis of and is an attractive therapeutic target in COVID-19.

Authors

Suchitra Kamle, Bing Ma, Chuan Hua He, Bedia Akosman, Yang Zhou, Chang-Min Lee, Wafik S. El-Deiry, Kelsey Huntington, Olin Liang, Jason T. Machan, Min-Jong Kang, Hyeon Jun Shin, Emiko Mizoguchi, Chun Geun Lee, Jack A. Elias

×

Figure 5

CHI3L1 is induced and regulates the expression of ACE2 and SPP in the lungs of aged mice.

Options: View larger image (or click on image) Download as PowerPoint
CHI3L1 is induced and regulates the expression of ACE2 and SPP in the lu...
(A) Comparison of the levels of mRNA encoding CHI3L1, ACE2, and SPP in lungs from 6- and 12-month-old WT mice evaluated by RT-qPCR. (B) WT mice were treated with IgG isotype antibody or anti-CHI3L1 (FRG) (200 μg/mouse, twice a week, i.p. injection) when the mice were between 6 and 12 months of age. At the end of this interval, the mice were sacrificed, and the levels of mRNA encoding pulmonary CHI3L1, ACE2, and SPP were evaluated by RT-qPCR. Ribosomal protein L13a (Rpl13a) was used as an internal control. Each value in A and B is from a different animal, and the mean ± SEM is illustrated. *P < 0.05, **P < 0.01 (Mann-Whitney U test).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts